Hemodynamic effects of endothelin-1 and big endothelin-1 in chronic hemodialysis patients

Journal of the American Society of Nephrology

Volumn 10, Issue 5, 1999, Pages 1037-1044

  Ottosson Seeberger, Astrid ^a,b   Ahlborg, Gunvor ^a   Hemsén, Anette ^a   Lundberg, Jan M ^a   Alvestrand, Anders ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BIG ENDOTHELIN 1; ENDOTHELIN 1;

ADULT; AGED; ARTICLE; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMODYNAMICS; HORMONE ACTION; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SPLANCHNIC BLOOD FLOW;

EID: 0032910483     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Ferro JC, Webb DJ: Endothelial dysfunction and hypertension. Drugs 53[Suppl 1]: 30-41, 1997
2. Rubanyi GM, Polokoff MA: Endothelins: Molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 46: 325-415, 1994
3. Haynes WG, Ferro CJ, O'Kane KPJ, Somerville D, Lomax CC, Webb DJ: Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation 93: 1860-1870, 1996
4. Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V: The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N Engl J Med 338: 784-790, 1998
5. Kiowski W, Sütsch G, Hunziker P, Müller P, Kim J, Oechslin E, Schmitt R, Jones R, Bertel O: Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 346: 732-736, 1995
6. Qiu S, Théroux P, Marcil M, Solymoss BC: Plasma endothelin-1 levels in stable and unstable angina. Cardiology 82: 12-18, 1993
7. Miyauchi T, Yanagisawa M, Tomizawa T, Sugishita Y, Suzuki N, Fujino M, Ajisaka R, Goto K, Masaki T: Increased plasma concentrations of endothelin-1 and big endothelin-1 in acute myocardial infarction. Lancet 2: 53-55, 1989
8. Lerman A, Holmes DR, Bell MR, Garratt KN, Nishimura RA, Burnett JC: Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans. Circulation 92: 2426-2431, 1995
9. Tomita K, Ujiie K, Nakanishi T, Tomita S, Matsuda O, Ando K, Shichiri M, Hirata Y, Marumo F: Plasma endothelin levels in patients with acute renal failure [Abstract]. N Engl J Med 321: 1127, 1989
10. Koyama H, Tabata T, Nishzawa Y, Inoue T, Morii H, Yamaji T: Plasma endothelin levels in patients with uraemia. Lancet 1: 991-992, 1989
11. Miyauchi T, Sugishita Y, Yamaguchi I, Ajisaka R, Tomizawa T, Onizuka M, Matsuda M, Kono I, Yanagisawa M, Goto K, Suzuki N, Matsumoto H, Masaki T: Plasma concentrations of endothelin-1 and endothelin-3 are altered differently in various pathophysiological conditions in humans. J Cardiovasc Pharmacol 17[Suppl 7]: S394-S397, 1991
12. Saito Y, Kazuwa N, Shirakami G, Mukoyama M, Arai H, Hosoda K, Suga S, Ogawa Y, Imura H: Endothelin in patients with chronic renal failure. J Cardiovasc Pharmacol 17[Suppl 7]: S437-S439, 1991
13. Ross RD, Kalidindi V, Vincent JA, Kassab J, Dabbagh S, Hsu JM, Pinsky WW: Acute changes in endothelin-1 after hemodialysis for chronic renal failure. J Pediatr 122: S74-S76, 1993
14. Raine AEG, Margreiter R, Brunner FP, Enrich JHH, Geerlings W, Landais P, Loirat C, Mallick NP, Selwood NH, Tufveson G, Valderrabano F: Report on management of renal failure in Europe, XXII, 1991. Nephrol Dial Transplant 7[Suppl 2]: 7-35, 1992
15. Weitzberg E, Ahlborg G, Lundberg JM: Long-lasting vasoconstriction and efficient regional extraction of endothelin-1 in human splanchnic and renal tissues. Biochem Biophys Res Commun 180: 1298-1303, 1991
16. Ahlborg G, Ottosson Seeberger A, Hemsén A, Lundberg JM: Big ET-1 infusion in man causes renal ET-1 release, renal and splanchnic vasoconstriction, and increased mean arterial blood pressure. Cardiovasc Res 28: 1559-1563, 1994
17. Pernow J, Kaijser L, Lundberg JM, Ahlborg G: Comparable potent coronary constrictor effects of endothelin-1 and big endothelin-1 in humans. Circulation 94: 2077-2082, 1996
18. Ahlborg G, Ottosson Seeberger A, Hemsén A, Lundberg JM: Central and regional hemodynamic effects during infusion of big endothelin-1 in healthy humans. J Appl Physiol 80: 1921-1927, 1996
19. Hemsén A, Ahlborg G, Ottosson Seeberger A, Lundberg JM: Metabolism of big endothelin-1 (1-38) and (22-38) in the human circulation in relation to production of endothelin-1 (1-21). Regul Pept 55: 287-297, 1995
20. Rowell LB, Blackmon JR, Bruce RA: Indocyanine green clearance and estimated hepatic blood flow during mild to maximal exercise in upright man. J Clin Invest 43: 1677-1690, 1964
21. Ruschitzka F, Noll G, Lachat M, Shaw S, Lüscher TF: Evidence of phosphoramidon- insensitive endothelin-converting enzymes in human vascular smooth muscle. 2nd Symposium on Endothelin Antagonism. [Abstract] Hospitalis 68: 9S, 1998
22. Winkles JA, Alberts GF, Brogi E, Libby P: Endothelin-1 and endothelin receptor mRNA expression in normal and atherosclerotic human arteries. Biochem Biophys Res Commun 191: 1081-1088, 1993
23. Ahlborg G, Weitzberg E, Lundberg JM: Circulating endothelin-1 reduces splanchnic and renal blood flow and splanchnic glucose production in humans. J Appl Physiol 79: 141-145, 1995
24. Demuth K, Blacher J, Guerin AP, Benoit MO, Moatti N, Safar ME, London GM: Endothelin and cardiovascular remodelling in end-stage renal disease. Nephrol Dial Transplant 13: 375-383, 1998
25. Mallamaci F, Parlongo S, Zoccali C: Influence of cardiovascular damage and residual renal function on plasma endothelin in chronic renal failure. Nephron 63: 291-295, 1993
26. Pernow J, Ahlborg G, Lundberg JM, Kaijser L: Long-lasting coronary vasoconstrictor effects and myocardial uptake of endothelin in humans. Acta Physiol Scand 159: 147-153, 1997
27. Krüger D, Sheikhzadeh A, Giannitsis E, Stierle U: Cardiac release and kinetics after severe short-lasting myocardial ischemia. J Am Coll Cardiol 30: 942-946, 1997
28. Ibels LS, Alfrey AC, Huffer WE, Craswell PW, Anderson JT, Weil R: Arterial calcification and pathology in uremic patients undergoing dialysis. Am J Med 66: 790-796, 1979
29. Kohno M, Murakawa K, Yasunari K, Yokokawa K, Horio T, Kurihara N, Takeda T: Prolonged blood pressure elevation after endothelin administration in bilaterally nephrectomized rats. Metab Clin Exp 38: 712-713, 1989
30. Vallance P, Leone A, Calver A, Collier J, Moncada S: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339: 572-575, 1992
31. Lundblad R, Moen O, Fosse E: Endothelin-1 and neutrophil activation during heparin-coated cardiopulmonary bypass. Ann Thorac Surg 63: 1361-1367, 1997
32. Herbelin A, Nguyen AT, Urena P, Descamps-Latscha B: Induction of cytokines by dialysis membranes in normal whole blood: A new in vitro assay for evaluating membrane biocompatibility. Blood Purif 10: 40-52, 1992
33. Niwa T, Fujishiro T, Uema K, Tsuzuki T, Tominaga Y, Emoto Y, Miyazaki T, Maeda K: Effect of hemodialysis on plasma levels of vasoactive peptides: Endothelin, calcitonin gene-related peptide and human atrial natriuretic peptide. Nephron 64: 552-559, 1993